Celgene Corp (CELG.OQ)
18 Jul 2018
Tue, Jul 10 2018
BRIEF-Celgene Corp Says Phase III Impassion130 Study Met Co-Primary Endpoint Of Progression-Free Survival
* ANTI-PD-L1 IMMUNOTHERAPY PLUS ABRAXANE® SIGNIFICANTLY REDUCED THE RISK OF DISEASE WORSENING OR DEATH IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER IN PHASE III IMPASSION130 STUDY
* DGAP-ADHOC: EVOTEC AND CELGENE ENTER INTO STRATEGIC ONCOLOGY PARTNERSHIP
Celgene Corp reported much-needed, stronger-than-expected first quarter results as profit and sales of several drugs exceeded Wall Street forecasts, and the U.S. biotechnology company said it would re-apply for approval of an important multiple sclerosis treatment in early 2019.
May 4 Celgene Corp reported much-needed, stronger-than-expected first quarter results as profit and sales of several drugs exceeded Wall Street forecasts, and the U.S. biotechnology company said it would re-apply for approval of an important multiple sclerosis treatment in early 2019.
* To resubmit ozanimod marketing application earlier than expected
* CELGENE REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS
May 4 Celgene Corp's quarterly profit fell about 9 percent despite the U.S. biotech reporting higher revenue, as its expenses surged.
* CELGENE CORP - ENTERED INTO AN AMENDED AND RESTATED CREDIT AGREEMENT TO EXTEND TERM OF CREDIT FACILITY TO APRIL 25, 2023 FROM APRIL 17, 2022 Source text (https://bit.ly/2HCsgr2) Further company coverage:
BRIEF-Celgene Corp Says CEO Mark Alles's FY 2017 Total Compensation Was $13.1 Mln Vs $12.2 Mln In FY 2016
* CELGENE CORP SAYS CEO MARK ALLES'S FY 2017 TOTAL COMPENSATION WAS $13.1 MILLION VERSUS $12.2 MILLION IN FY 2016 - SEC FILING
* ZYMEWORKS AND CELGENE EXPAND BISPECIFIC ANTIBODY COLLABORATION
- You Can't Go Wrong Buying Netflix On Dips - Cramer's Mad Money (7/17/18)
- The Smart Way To Find Undervalued Stocks
- Biotech Analysis Central Pharma News: Celgene's Protocol Change, Roche's BLA For Herceptin, Amgen's Resubmission For Osteoporosis
- Your Daily Pharma Scoop: Zogenix Zooms, Zynerba's Changing Fortunes, AbbVie Proceeds
- Your Daily Pharma Scoop: IsoRay Doubles, OncoCyte Zooms, Celgene Sluggish
- 3 Things In Biotech, June 11: Acceleron's Second Punch, Advaxis's Letdown, Seattle's New Hope